利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.021 秒)

    USE AND COMPOSITION FOR TREATING DEMENTIA
    1.
    发明公开
    USE AND COMPOSITION FOR TREATING DEMENTIA 审中-公开

    公开(公告)号：EP4088717A1

    公开(公告)日：2022-11-16

    申请号：EP22177194.2

    申请日：2009-03-17

    申请人： Chase Pharmaceuticals Corporation

    发明人： CHASE, Thomas, N. ,  CLARENCE-SMITH, Ms. Kathleen, E.

    IPC分类号： A61K31/27 ,  A61K31/445 ,  A61K31/4747 ,  A61K31/55 ,  A61P25/28 ,  A61K31/325 ,  A61K31/46 ,  A61K31/473 ,  A61K45/06

    摘要： There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-selective, peripheral anticholinergic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-selective, peripheral anticholinergic agent (nsPAChA) for the preparation of a pharmaceutical composition for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia and pharmaceutical compositions comprising a non-selective peripheral anticholinergic agent of formula II as illustrated in the description and an acetylcholine esterase inhibitor are also described.

    OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION
    5.
    发明公开
    OXYBUTYNIN TRANSDERMAL THERAPEUTIC SYSTEM MUSCARINIC AGONIST COMBINATION 审中-公开
    氧化苦素透皮治疗系统肌肉调节激素组合

    公开(公告)号：EP3265128A1

    公开(公告)日：2018-01-10

    申请号：EP16762194.5

    申请日：2016-03-04

    申请人： Chase Pharmaceuticals Corporation

    发明人： CHASE, Thomas N. ,  CLARENCE-SMITH, Kathleen E.

    IPC分类号： A61K45/06

    CPC分类号： A61K31/216 ,  A61K9/0014 ,  A61K9/12 ,  A61K9/703 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4439 ,  A61K45/06 ,  A61K47/06 ,  A61K47/10 ,  A61K2300/00 ,  A61P25/28

    摘要： Pharmaceutical compositions and combinations containing a muscarinic receptor antagonist, such as oxybutynin in a transdermal therapeutic system, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and methods of using the same for treatment of hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The respective pharmaceutical compositions and combinations of the present invention allow for safe administration of high doses of muscarinic receptor agonist, and improved efficacy of the muscarinic receptor agonist for treatment of hypocholinergic disorders of the central nervous system. The pharmaceutical compositions and combinations also allow for a maximum supply of acetylcholine to the central nervous system, when an acetyl cholinesterase inhibitor is used in combination with a muscarinic receptor antagonist and a muscarinic receptor agonist.

    COMBINATION OF A NSPACHA (PERIPHERAL ANTICHOLINERGIC AGENT) LIKE SOLIFENACIN AND AN ACHEI (ACETYL CHOLINE ESTERASE INHIBITOR) LIKE DONEPEZIL FOR TREATING DEMENTIA
    7.
    发明公开
    COMBINATION OF A NSPACHA (PERIPHERAL ANTICHOLINERGIC AGENT) LIKE SOLIFENACIN AND AN ACHEI (ACETYL CHOLINE ESTERASE INHIBITOR) LIKE DONEPEZIL FOR TREATING DEMENTIA 审中-公开
    NSPACHA组合（抗胆碱能PERIPHÄREMACTIVE）AS索非那新AND A的AChEI（乙酰胆碱酯酶抑制剂）HOW多奈哌齐在使用治疗痴呆

    公开(公告)号：EP3178477A1

    公开(公告)日：2017-06-14

    申请号：EP17150365.9

    申请日：2009-03-17

    申请人： Chase Pharmaceuticals Corporation

    发明人： CHASE, Thomas, N. ,  CLARENCE-SMITH, Kathleen, E.

    IPC分类号： A61K31/27 ,  A61K31/445 ,  A61K31/4747 ,  A61K31/55 ,  A61P25/28 ,  A61K31/325 ,  A61K31/46 ,  A61K31/473 ,  A61K45/06

    CPC分类号： A61K31/46 ,  A61K31/27 ,  A61K31/325 ,  A61K31/445 ,  A61K31/473 ,  A61K31/4747 ,  A61K31/55 ,  A61K45/06 ,  A61K2300/00

    摘要： There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-selective, peripheral anticholinergic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-selective, peripheral anticholinergic agent (nsPAChA) for the preparation of a pharmaceutical composition for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia and pharmaceutical compositions comprising a non-selective peripheral anticholinergic agent of formula II as illustrated in the description and an acetylcholine esterase inhibitor are also described.

    摘要翻译： 中描述了一种方法，用于通过用非选择性降低在组合由所述的AChEI的施用伴随的不利影响增加最大耐受剂量并且因此在从阿尔茨海默氏型痴呆的患者的乙酰胆碱酯酶抑制剂（的AChEI）的功效 ，外周抗胆碱能剂，由此在增强在所述患者的CNS乙酰胆碱酯酶抑制得以实现，在所述患者阿尔茨海默型痴呆症的症状的减轻由此提高到更大的程度。 用于药物组合物的制备中的使用非选择性的，外周抗胆碱能剂（nsPAChA）用于增加最大耐受剂量，因此乙酰胆碱酯酶抑制剂（的AChEI）在患者患有阿耳茨海默氏型痴呆症的功效和 药物组合物包含式II的非选择性周抗胆碱能剂如在说明书和乙酰胆碱酯酶抑制剂示出被如此描述。

    USE AND COMPOSITION FOR TREATING DEMENTIA
    8.
    发明授权
    USE AND COMPOSITION FOR TREATING DEMENTIA 有权
    用于治疗痴呆症的用途和组合物

    公开(公告)号：EP2271218B1

    公开(公告)日：2017-05-24

    申请号：EP09726036.8

    申请日：2009-03-17

    申请人： Chase Pharmaceuticals Corporation

    发明人： CHASE, Thomas, N. ,  CLARENCE-SMITH, Kathleen, E.

    IPC分类号： A61K31/27 ,  A61K31/325 ,  A61K31/445 ,  A61K31/46 ,  A61K31/473 ,  A61K31/4747 ,  A61K31/55 ,  A61P25/28 ,  A61K45/06

    CPC分类号： A61K31/46 ,  A61K31/27 ,  A61K31/325 ,  A61K31/445 ,  A61K31/473 ,  A61K31/4747 ,  A61K31/55 ,  A61K45/06 ,  A61K2300/00

    摘要： There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-selective, peripheral anticholinergic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-selective, peripheral anticholinergic agent (nsPAChA) for the preparation of a pharmaceutical composition for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia and pharmaceutical compositions comprising a non-selective peripheral anticholinergic agent of formula II as illustrated in the description and an acetylcholine esterase inhibitor are also described.

    摘要翻译： 描述了一种通过给予所述AChEI并结合非选择性化合物减少伴随的副作用来增加最大耐受剂量并由此增加患有阿尔茨海默型痴呆的患者中乙酰胆碱酯酶抑制剂（AChEI）的功效的方法 ，由此实现了所述患者的CNS中增强的乙酰胆碱酯酶抑制作用，从而改善了所述患者的阿尔茨海默型痴呆症状的症状。 非选择性外周抗胆碱能药物（nsPAChA）在制备用于增加阿尔茨海默型痴呆患者的最大耐受剂量和因此乙酰胆碱酯酶抑制剂（AChEI）功效的药物组合物中的用途和 还描述了包含如说明书中所示的式II的非选择性外周抗胆碱能剂和乙酰胆碱酯酶抑制剂的药物组合物。

    ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS
    9.
    发明公开
    ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS 审中-公开
    神经保护性抗菌药ZUSAMMENSETZUNG UND VERFAHREN

    公开(公告)号：EP2892514A1

    公开(公告)日：2015-07-15

    申请号：EP13836121.7

    申请日：2013-09-05

    申请人： Chase Pharmaceuticals Corporation

    发明人： CLARENCE-SMITH, Kathleen E. ,  CHASE, Thomas N.

    IPC分类号： A61K31/00

    CPC分类号： A61K31/46 ,  A61K9/2063 ,  A61K9/4858 ,  A61K31/166 ,  A61K31/27 ,  A61K31/325 ,  A61K31/40 ,  A61K31/4178 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4465 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/55 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to a pharmaceutical composition comprising propiverine, trospium or glycopyrrolate; and a non-anticholinergic antiemetic agent. It is also related to a pharmaceutical composition comprising a high dose of solifenacin or a pharmaceutically acceptable salts thereof; and a non-anticholinergic antiemetic agent. Pharmaceutical compositions containing high dose of nsPAChA for use for increasing the AChEI blood concentrations and for combating neurodegeneration are also described. The invention also relates to a method for inducing neuroprotection and combating neurodegeneration in a patient suffering from Alzheimer type dementia as well as to a method for increasing the blood levels of an acetyl choline esterase inhibitor (AChEI) in a human subject treated with an AChEI dose.

    摘要翻译： 本发明涉及药物组合物，其包含propropine，trospium或glycopyrrolate; 和非抗胆碱能止吐剂。 它还涉及包含高剂量的索非那嗪或其药学上可接受的盐的药物组合物; 和非抗胆碱能止吐剂。 还描述了含有高剂量nsPAChA用于增加AChEI血液浓度和抵抗神经变性的药物组合物。 本发明还涉及在患有阿尔茨海默氏型痴呆症的患者中诱导神经保护和对抗神经变性的方法以及增加用AChEI剂量治疗的人类受试者中乙酰胆碱酯酶抑制剂（AChEI）的血液水平的方法 。